LDN-212854 [1432597-26-6]
Cat# HY-15897-5mg
Size : 5mg
Brand : MedChemExpress
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC).
For research use only. We do not sell to patients.
LDN-212854 Chemical Structure
CAS No. : 1432597-26-6
This product is a controlled substance and not for sale in your territory.
Based on 1 publication(s) in Google Scholar
View All TGF-β Receptor Isoform Specific Products:
Description |
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC)[1][2]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
In Vitro |
LDN-212854 (0-3.815 μM) blocks the phosphorylation of SMAD1/5/8 induced by BMP7 in BMPR2−/− cells[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[1]
|
||||||||||||||||
In Vivo |
LDN-212854 (intraperitoneal injection, 6 mg/kg, twice daily for 4 weeks) potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
Molecular Weight |
406.48 |
||||||||||||||||
Formula |
C25H22N6 |
||||||||||||||||
CAS No. |
1432597-26-6 |
||||||||||||||||
Appearance |
Solid |
||||||||||||||||
Color |
Light yellow to yellow |
||||||||||||||||
SMILES |
C12=C(C3=C4N=CC(C5=CC=C(N6CCNCC6)C=C5)=CN4N=C3)C=CC=C1N=CC=C2 |
||||||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
Storage |
|
||||||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : ≥ 30 mg/mL (73.80 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||||||
Purity & Documentation |
Purity: 99.70% |
||||||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 2.4601 mL | 12.3007 mL | 24.6015 mL | 61.5036 mL |
5 mM | 0.4920 mL | 2.4601 mL | 4.9203 mL | 12.3007 mL | |
10 mM | 0.2460 mL | 1.2301 mL | 2.4601 mL | 6.1504 mL | |
15 mM | 0.1640 mL | 0.8200 mL | 1.6401 mL | 4.1002 mL | |
20 mM | 0.1230 mL | 0.6150 mL | 1.2301 mL | 3.0752 mL | |
25 mM | 0.0984 mL | 0.4920 mL | 0.9841 mL | 2.4601 mL | |
30 mM | 0.0820 mL | 0.4100 mL | 0.8200 mL | 2.0501 mL | |
40 mM | 0.0615 mL | 0.3075 mL | 0.6150 mL | 1.5376 mL | |
50 mM | 0.0492 mL | 0.2460 mL | 0.4920 mL | 1.2301 mL | |
60 mM | 0.0410 mL | 0.2050 mL | 0.4100 mL | 1.0251 mL |
LDN-212854 Related Classifications
- TGF-beta/Smad
- TGF-β Receptor